Benfotiamine
A fat-soluble form of vitamin B1 that achieves several-fold higher tissue thiamine levels than ordinary thiamine, with moderate evidence for diabetic neuropathy symptoms and early-stage trials in Alzheimer's disease.
At a Glance
- Best known for
- Raises thiamine levels in blood and nerves more effectively than thiamine, Reduces diabetic neuropathy pain and symptoms in several trials, Blocks formation of advanced glycation end products (AGEs)
- Evidence
- Moderate
- Typical dose
- 300 mg twice daily (600 mg/day)
- Type
- Vitamin
What is Benfotiamine?
Benfotiamine is a synthetic derivative of thiamine (vitamin B1) developed in Japan in the 1950s to overcome thiamine's poor absorption. Unlike water-soluble thiamine, which depends on a saturable transporter that limits uptake to a few milligrams per dose, benfotiamine is fat-soluble and passes through the gut wall by diffusion before being converted to thiamine. This produces blood and tissue levels roughly 5 times higher than equivalent doses of thiamine. It has been prescribed in Germany for decades for diabetic nerve damage and alcohol-related neuropathy, and in the 2000s research showed it blocks three of the major pathways by which high blood sugar damages blood vessels and nerves, broadening interest to diabetic kidney and eye disease and, more recently, to Alzheimer's disease, where brain glucose metabolism and thiamine-dependent enzymes are impaired.
Known Health Benefits
How It Works
Once absorbed, benfotiamine is converted to thiamine and then to thiamine pyrophosphate (TPP), the active cofactor. High TPP levels strongly activate transketolase, the enzyme that shunts excess glucose metabolites (particularly glyceraldehyde-3-phosphate and fructose-6-phosphate) into the pentose phosphate pathway. This diverts them away from three damaging pathways activated by high blood sugar: formation of advanced glycation end products (AGEs), activation of protein kinase C, and the hexosamine pathway. AGEs stiffen proteins and trigger inflammation through the RAGE receptor; benfotiamine reduces AGE formation and RAGE signaling. In the brain, benfotiamine increases TPP-dependent enzyme activity, reduces amyloid plaque and tau phosphorylation in mouse models, and may improve glucose utilization in affected regions. Nerve benefits likely combine metabolic normalization with improved nerve conduction from restored thiamine status.
What Research Says
Several small randomized trials from Germany support benfotiamine in diabetic polyneuropathy. The BENDIP study (2008, 181 patients) found 600 mg daily for 6 weeks improved neuropathy symptom scores, particularly pain, compared with placebo, with 300 mg showing a smaller effect. An earlier 2005 trial found similar symptom improvement. However, a 2012 trial of 900 mg daily for 12 months in type 1 diabetes found no effect on nerve function tests or inflammation markers, and a 2010 trial found no benefit on kidney function markers despite reduced AGE levels — the picture is mixed and larger, longer trials are lacking. A 2006 study found that benfotiamine prevented the blood vessel dysfunction and AGE spike caused by a high-AGE meal in people with diabetes. In Alzheimer's, a 2020 phase II trial of 70 people with mild cognitive impairment or mild Alzheimer's found 600 mg benfotiamine daily for 12 months was associated with less cognitive decline on one measure and reduced AGE levels, with a larger trial now underway. Alcohol-related neuropathy trials from the 1990s were positive but small. Benfotiamine is consistently safe but its clinical benefits remain moderate and not fully confirmed.
Active Compounds
Benfotiamine (S-benzoylthiamine O-monophosphate), a synthetic lipid-soluble thiamine derivative converted to thiamine in the body
Forms & Bioavailability
Benfotiamine is dephosphorylated in the gut wall to S-benzoylthiamine, which diffuses into cells and is converted to thiamine. Compared with thiamine hydrochloride, it produces about 5-fold higher peak blood thiamine levels and higher TPP in red blood cells and tissues, with a longer duration. Animal studies suggest it raises thiamine in peripheral nerves, liver, kidney, and muscle more than in the brain, which is one reason sulbutiamine is sometimes preferred for central nervous system targets, though human Alzheimer's trials have used benfotiamine with measurable effects. Taking it with food is fine and may aid absorption slightly. Dividing the daily dose into 2–3 portions maintains steadier levels.
Dosage Guidance
| Use Case | Dosage |
|---|---|
| Diabetic peripheral neuropathy (studied) | 300 mg twice daily (600 mg/day) |
| Alcohol-related neuropathy | 300–600 mg daily |
| AGE reduction / diabetic vascular support | 300 mg daily |
| Cognitive support in early Alzheimer's (studied) | 300 mg twice daily |
| General thiamine supplementation | 150–300 mg daily |
Always consult a healthcare provider for personalized dosing.
Natural Food Sources
- Benfotiamine does not occur in food; it is synthetic
- Related natural fat-soluble thiamine disulfides (allithiamine) form in garlic and onions when thiamine meets allicin
- Thiamine-rich foods: pork, whole grains, legumes, sunflower seeds, nutritional yeast
Potential Side Effects
Rare; mild stomach upset, skin rash, or body odor reported occasionally; no toxicity found at doses up to 600 mg daily in trials
Who Should Avoid It
- Known allergy to thiamine or benzoyl compounds
- No upper limit established; doses to 900 mg/day used in trials without toxicity
- Use alongside, not instead of, glucose control and prescribed neuropathy treatment
- Discuss with oncologist during chemotherapy, as thiamine status can affect some regimens
Pregnancy & Lactation
Benfotiamine has not been studied in pregnancy or breastfeeding. Although it is simply a form of vitamin B1 and converts to thiamine, the safety of high doses in these periods is not established. Pregnant and nursing women should meet thiamine needs with standard prenatal vitamins and use benfotiamine only if a doctor recommends it for a specific indication.
Known Drug Interactions
May enhance blood sugar-lowering drugs modestly; loop diuretics and metformin increase thiamine needs; may affect dosing of some chemotherapy agents (5-FU) — discuss with oncologist; otherwise few known interactions
Evidence Classification
Supported by cohort studies, case-control studies, or multiple observational studies with consistent findings.
Frequently Asked Questions
Why benfotiamine instead of regular thiamine?
Regular thiamine is absorbed by a transporter that saturates at low doses, so taking 100 mg yields only a few milligrams absorbed. Benfotiamine is fat-soluble and bypasses the transporter, producing about 5 times higher blood and tissue levels. For correcting a simple deficiency, ordinary thiamine is adequate and cheaper; for conditions where high tissue thiamine is the goal — diabetic complications, neuropathy, possibly cognitive decline — benfotiamine is the better-studied choice.
Does benfotiamine help diabetic neuropathy?
Several small trials show reduced pain and symptom scores within 6 weeks at 600 mg daily, while others, including a 12-month trial, found no improvement in objective nerve tests. It appears to help symptoms in some people and is very safe, which makes it a reasonable adjunct, often combined with alpha-lipoic acid and methylcobalamin. It is not a substitute for blood sugar control, which remains the most effective way to protect nerves.
Can benfotiamine prevent Alzheimer's?
It is too early to say. Thiamine-dependent enzymes are reduced in Alzheimer's brains, and a 2020 phase II trial found benfotiamine slowed decline on a cognitive measure in people with mild disease. A larger trial is in progress. Until it reports, benfotiamine is a plausible, low-risk intervention for people with early cognitive impairment, but not a proven one.
How long does benfotiamine take to work?
Tissue thiamine levels rise within days, but symptom improvement in neuropathy trials took 3–6 weeks at 600 mg daily. For AGE-related and vascular endpoints, benefits are measured over months. If no improvement in neuropathy symptoms is noticed by 12 weeks, it is reasonable to stop.
References
- Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Exp Clin Endocrinol Diabetes (2008)
- Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. Gibson GE, Luchsinger JA, Cirio R, et al.. J Alzheimers Dis (2020)
- Thiamin — Fact Sheet for Health Professionals. National Institutes of Health, Office of Dietary Supplements. NIH ODS (2023)View study
Related Health Conditions
Related Supplements
Have questions about Benfotiamine?
Ask Mother Nature AI about dosing, interactions with your medications, whether it fits your health goals, and more — personalized to your health profile.
This entry is for educational purposes only. It is not medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement regimen, especially if you take medications or have health conditions.